NAD O.K. with ads comparing Aleve to Advil
This article was originally published in The Tan Sheet
Executive Summary
Bayer Healthcare's ads comparing Aleve to Wyeth Consumer Healthcare's Advil meet the National Advertising Division's approval. According to a Sept. 9 report, NAD reviewed the ads after Wyeth complained claims that Aleve is "the best value" and "Just 2 Aleve = 4 Advil" are implied superiority claims. NAD disagreed, finding the pill-count comparison is based appropriately on FDA-approved labels for Aleve and Advil. Wyeth also complained Bayer claims Aleve can "stop pain all day" and provide "all day pain-free movement" are not but should be supported by studies. NAD disagreed, noting "no reasonable consumer would expect total pain relief.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.